Discussions emphasize the need for increased effort and cooperation in Latin America to improve regulation and effectiveness of orphan drugs, using words like 'effort,' 'cooperation,' and 'regulate,' which highlight the shared recognition of challenges and potential benefits of stronger collaboration in managing rare diseases.
AgreementModerate agreement
Most discussions agree on the importance of effort and cooperation in managing rare disease treatments, reflecting a consensus on the need for system improvements.
InterestModerate interest
Posts show moderate interest by emphasizing the need for regulation and collaboration, highlighting the relevance of the topic without deep dives into specifics.
EngagementModerate engagement
Participants demonstrate some engagement by referencing broader ideas like cooperation and regulation, but lack detailed analysis or critical discussion.
ImpactNeutral impact
The discussions acknowledge the importance of coordinated efforts, but don't suggest immediate or wide-reaching changes, indicating a moderate perceived impact.
Abstract in brief
The text discusses the development and regulation of orphan medicinal products (drugs for rare diseases) in the European Union (EU) and the United States (US), highlighting the number of designations, approvals, and indications up to December 2015.
In the EU, there were 1,264 orphan drug designations with 133 approved products covering 179 indications, while in the US, 3,082 designations led to 415 approved products covering 521 indications.
Despite incentives, certain rare disease categories lack marketed treatments in the EU, particularly for bone, connective tissue, and reproductive diseases, and many orphan drugs are approved for children; if all approvals were combined, many additional indications could be covered.]
Lo que se necesita. Esfuerzo y cooperación en America Latina para regular y consensuar efectividad en el uso de drogas huérfanas para Enfermedades Poco Frecuentes https://t.co/Wf0bYCyGF7
Feb 16, 2023 · 3 likes · 1 share · 5,031 followersView post →
DS
Daniel Suárez
@danielsuarez100 · X
RT @Ekonsalud: Lo que se necesita. Esfuerzo y cooperación en America Latina para regular y consensuar efectividad en el uso de drogas huérf…
This episode provides investors with a thorough understanding of Orphan Drug status and designation. Understanding this classification is crucial for investing in healthcare companies developing treatments for rare…
This episode introduces investors to the regulatory approval process for orphan drugs, covering timelines, pathways like Fast Track and PRIME, and options to expedite bringing treatments to market for rare diseases.
Lo que se necesita. Esfuerzo y cooperación en America Latina para regular y consensuar efectividad en el uso de drogas huérfanas para Enfermedades Poco Frecuentes https://t.co/Wf0bYCyGF7
Feb 16, 2023 · 3 likes · 1 share · 5,031 followersView post →
N
Orphan drugs | PPTX
News
doi:10.1186/s13023-017-0617-1. ISSN 1750-1172. PMC 5376695. PMID 28372595 4. Global orphan drug market to reach US$120 billion by 2018 (press release), New ...
ES
DS
